RA0386

antibody from Oursmab

Targeting: IL1RL2 IL1R-rp2, IL1RRP2

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0386

Provider

Oursmab

Product name

Imsidolimab (Biosimilar Reference Antibody) (IL36R)

Antibody type

Monoclonal

Description

Imsidolimab (development code ANB-019) is an investigational, fully human monoclonal antibody being developed for the treatment of auto-inflammatory skin diseases, most notably generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP). It functions as a selective interleukin-36 receptor (IL-36R) antagonist. By binding with high affinity to IL-36R, imsidolimab blocks the receptor from interacting with its pro-inflammatory ligands (IL-36¦Á, IL-36¦Â, and IL-36¦Ã). This blockade inhibits the downstream activation of nuclear factor-kappa B (NF-¦ÊB) and mitogen-activated protein kinase (MAPK) signaling pathways, thereby suppressing the intense neutrophilic inflammation and pustule formation that characterize these debilitating skin diseases.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.